Search Results

Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario

• Authors : Centers for Disease Control and Prevention; Biomedical Advanced Research and Development Authority

• Source: A Field Study to Evaluate the Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario

Record details

Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients

• Source: Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated RecipientsDalton R. Genetic

Record details

Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

• Authors : Centers for Disease Control and Prevention; Department of Health and Human Services

• Source: An Observational Clinical Study of AIGIV Use in Sporadic Cases of Systemic Anthrax

Record details

A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

• Authors : Centers for Disease Control and Prevention; Department of Health and Human Services

• Source: A Field Study for the Evaluation of AIGIV Clinical Benefit and Safety in the Treatment of Patients With Inhalational Anthrax in a Broad Exposure Event Scenario

Record details

Anthrax AV7909 Liquid vs Lyophilized

• Source: A Phase 1, Randomized, Parallel-Group, Double-Blind Trial of AV7909 (Liquid) and Thermostable AV7909 (Lyophilized) in Healthy Adult Volunteers

Record details

Anthrax AV7909 Boost Evaluation Study (ABESt)

• Authors : Rho Federal Systems Division, Inc.; ICON plc

• Source: A Randomized, Double-blinded, Multicenter Study in Healthy Adults to Evaluate Safety and Immunogenicity of AV7909 Administered At Two Dose Levels on Two Vaccination Schedules, Including a Primary

Record details

Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change (AVRP)

• Authors : Walter Reed Army Institute of Research (WRAIR); Baylor College of Medicine; University of Alabama at Birmingham

• Source: Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose ReductionMarano N, Plikaytis BD,

Record details

A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax

• Authors : Qin Ning, Professor

• Source: A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax

Record details

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

• Source: A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4

Record details

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

• Authors : National Institute of Allergy and Infectious Diseases (NIAID)

• Source: A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax

Record details